Retatrutide
Also known as: LY3437943, Triple G
Primary recreational use: Weight loss
What is Retatrutide?
Retatrutide is a novel peptide developed as a triple agonist of GLP-1, GIP, and glucagon receptors, primarily for weight loss and diabetes management. It has shown unprecedented results in clinical trials, achieving significant weight reduction and improved glycemic control. Currently in Phase 3 trials, Retatrutide is not yet FDA-approved but is anticipated for approval around 2026-2027. Key concerns include common gastrointestinal side effects and its investigational status.
Primary Benefits
Promotes fat loss. Improves glycemic control. Enhances metabolic health.
How It Works
Retatrutide works by simultaneously activating GLP-1, GIP, and glucagon receptors. This leads to appetite suppression, enhanced insulin response, increased energy expenditure, and fat oxidation. The synergy of these pathways contributes to its significant weight loss and metabolic benefits.
Safety Tips
Precautions reported in community discussions and literature. This is not a complete list.
- 1.DON'T start with a high dose; begin with 0.5-1mg per week and titrate slowly.
- 2.DON'T use if you have a history of medullary thyroid carcinoma or MEN2 syndrome.
- 3.DON'T skip weekly injections as consistency is crucial for effective results.
- 4.DON'T rely on non-pharmaceutical-grade sources; verify authenticity to avoid counterfeit products.
- 5.DON'T freeze the reconstituted solution; store it between 2-8°C in a refrigerator.
- 6.DON'T exceed 12mg weekly without consulting a healthcare provider.
- 7.DON'T use BAC saline for reconstitution as it may cause precipitation.
- 8.DON'T inject without rotating sites; use abdomen, thigh, or upper arm and rotate weekly.
- 9.DON'T use in combination with GLP-1 agonists without medical advice.
- 10.DON'T ignore signs of pancreatitis such as severe abdominal pain.
Use Contexts
Different purposes have different protocols, dosing, and considerations
Weight Loss
strong evidenceRetatrutide is used in trials to promote significant weight loss through its triple agonist mechanism.
Evidence: Multiple Phase 2 and 3 trials have demonstrated robust weight reduction and improvements in metabolic markers.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Morning, same day each week
Notes: Begin with 0.5-1mg and gradually escalate to minimize GI side effects.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| Conservative Starting Dose (Week 1-4) | 0.5 mg weekly | Once weekly | Subcutaneous injection |
| Standard Escalation (Week 8-12) | 2 mg weekly | Once weekly | Subcutaneous injection |
| Maximum Efficacy (Week 20+) | 12 mg weekly | Once weekly | Subcutaneous injection |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Pancreatitis
- Dysesthesia
Injection-Specific Warnings
- Reactions at the injection site
- Importance of sterile technique
Storage
Type 2 Diabetes Management
strong evidenceResearch is examining Retatrutide's efficacy in improving glycemic control in Type 2 Diabetes patients.
Evidence: Phase 2 trials have shown significant HbA1c reduction and glycemic improvements.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Morning, same day each week
Notes: Start with a conservative dose (0.5-1mg) to minimize side effects.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| Type 2 Diabetes - Maintenance | 4-8 mg weekly | Once weekly | Subcutaneous injection |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- None listed
Injection-Specific Warnings
- Monitor blood glucose levels regularly
Storage
Obesity with liver disease (MASLD)
moderate evidenceInvestigated in trials for its ability to reduce liver fat and improve metabolic outcomes in patients with metabolic-associated steatotic liver disease.
Evidence: Phase 2 trials indicate potential for significant liver fat reduction and metabolic improvement.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Morning, same day each week
Notes: Administer consistently for optimal liver health benefits.
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Liver abnormalities
Injection-Specific Warnings
- Regular liver function monitoring recommended
Storage
Harm Reduction Information
Quality Concerns
- Counterfeit products due to high demand
- Inconsistent cold-chain management
- Potential mislabeling as different peptides or strengths
Safety Tips
- Verify source for authenticity and pharmaceutical-grade quality
- Store reconstituted product at 2-8°C and protect from light
- Start with the lowest recommended dose and escalate slowly
- Use sterile technique for reconstitution and administration
- Rotate injection sites weekly to prevent tissue damage
Warning Signs to Stop
- Severe abdominal pain indicating potential pancreatitis
- Rapid heart rate or palpitations
- Signs of allergic reaction such as rash or difficulty breathing
- Unexplained swelling or severe gastrointestinal distress
Seek Medical Help Immediately If
- Suspected pancreatitis
- Severe allergic reaction
- Uncontrolled vomiting or diarrhea lasting more than 24 hours
Frequently Asked Questions
Common questions about Retatrutide
How long until I see effects?
With Retatrutide, some effects like appetite suppression may be noticeable within the first 1-2 weeks, but significant weight loss typically occurs over several weeks.
What time of day should I take it?
Retatrutide should be administered once weekly, ideally in the morning to allow for monitoring of any side effects.
How can I minimize side effects?
To minimize side effects with Retatrutide, start with a low dose and increase gradually, ensuring proper hydration and avoiding heavy meals shortly after dosing.
Does tolerance develop?
Tolerance to Retatrutide is not commonly reported; however, it is important to follow dosing protocols and monitor effectiveness over time.
How should I store it?
Store Retatrutide in its reconstituted form in a refrigerator at 2-8°C, and ensure it's protected from light.
Do I need to cycle it?
Retatrutide is designed for continuous therapy without cycling, with long-term use expected to maintain its benefits.
Can I combine it with other peptides?
While Retatrutide can interact with other peptides, it's best to consult with a healthcare provider to ensure safe and effective combinations.
Reported Combinations
Compounds reported to be used alongside Retatrutide in community discussions
Semaglutide
Both target GLP-1, enhancing weight loss effects.
Tirzepatide
Dual GIP/GLP-1 receptor agonism complements Retatrutide.
Metformin
Improves glucose control when used with Retatrutide.
Adequate Sleep
Enhanced weight loss and recovery.
Fasted Cardio
Increases fat oxidation and complements Retatrutide's effects.
High-Protein Diet
Supports muscle retention during weight loss.
Reported Interactions
Interactions reported in literature and community discussions.
Increased risk of hypoglycemia when combined with Retatrutide.
Compatible but should be monitored for enhanced glucose-lowering effect.
Timing of administration may affect efficacy.
Monitor for increased bleeding risk.
Generally compatible with no known serious interactions.
Reconstitution Calculator
100 units = 1 mL
Safety Tips
- Always consult a licensed medical professional for dosing and reconstitution instructions.
- Always double check your units. Mixing up mg and mcg can be very dangerous.
- Make sure to select your syringe type. U-100 and U-50 syringes have different units.
- Ensure you're not adding more BAC than your vial can hold. Most vials have maximum capacities listed.
This calculator is for informational and educational purposes only. It does not provide medical advice, dosing recommendations, or safety determinations. Reference ranges shown are compiled from publicly available sources and are not a substitute for guidance from a licensed healthcare professional.
Legal Status by Region
Regulatory status varies by country
USA
investigational
UK
investigational
EU
investigational
Australia
investigational
Canada
investigational
Explore More Research
Browse our database of peptide research information compiled from published literature and community sources.
Citations
Last updated: October 5, 2023